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Lewy bodies comprised of aggregates of α-synuclein (αS) in the brain are the main 
histopathological features of Lewy body diseases (LBD) such as Parkinson's disease and 
dementia with Lewy bodies. Mutations such as E46K, A30P and A53T in the αS gene cause 
autosomal dominant LBD in a number of kindreds. Although these mutations accelerate fibril 
formation, their precise effects at early stages of the αS aggregation process remain unknown. To 
answer this question, we examined the aggregation including monomer conformational dynamics 
and oligomerization of the E46K, A30P, A53T and A30P/A53T mutations and wild type (WT) 
using thioflavin S assay, circular dichroism spectroscopy, photo-induced cross-linking of 
unmodified proteins, electron microscopy, and atomic force microscopy. Relative to WT αS, 
E46K αS accelerated the kinetics of the secondary structure change and oligomerization, whereas 
A30P αS decelerated them. These effects were reflected in changes in average oligomer size. 
The mutant oligomers of E46K αS functioned as fibril seeds significantly more efficiently than 
those of WT αS, whereas the mutant oligomers of A30P αS were less efficient.  Our results that 
mutations of familial LBD had opposite effects at early stages of αS assembly may provide new 
insight into the molecular mechanisms of LBD. 
 






   Parkinson’s disease (PD) is a neurodegenerative movement disorder characterized by the 
selective loss of dopaminergic neurons from the substantial nigra, and the appearance of 
intraneuronal inclusions, called Lewy bodies (LBs) and Lewy neurites.  LBs are composed of a 
dense core of fibrillar structures whose major component is α-synuclein (αS) (Baba et al., 1998; 
Spillantini et al., 1998).  Aggregation of αS is considered to be an important and, probably, 
seminal step in the development of Lewy body diseases (LBD) including PD and dementia with 
LBs (DLB) and other α-synucleinopathies such as multiple system atrophy (Ono et al., 2008; 
Uversky, 2007).   
  Genetic studies of the αS gene in familial cases of PD and DLB have demonstrated that 
expression of abnormal αS or overexpression of normal αS is associated with these diseases.  
Pathogenic missense mutations [A53T (Polymeropoulos et al., 1997), A30P (Kruger et al., 1998), 
and E46K (Zarranz et al., 2004) and multiplication (Chartier-Harlin et al., 2004; Farrer et al., 
2004; Fuchs et al., 2007; Ibanez et al., 2004; Nishioka et al., 2006; Singleton et al., 2003)] of the 
αS gene have been identified in kindreds of autosomal dominantly inherited familial PD and 
DLB (Fig. 1).  
  αS is a 140-amino acid protein, having an N-terminal domain with seven imperfect KTKEGV 
sequence repeats, followed by a hydrophobic central region (non-amyloid β-protein (Aβ) 
component of Alzheimer disease (NAC)) and C-terminal domain with a large portion of acidic 
residues.  The repeat region at the N-terminus has been assumed to form an amphipathic α-helix 
by binding to phospholipid (Davidson et al., 1998).  Circular dichroism and Fourier-transform 
IR analysis revealed that αS is a natively unfolded protein without a highly ordered secondary 
structure (Uversky et al., 2001).  Recent nuclear magnetic resonance (NMR) analyses have 
revealed three intramolecular long range interactions. These interactions are between the highly 
hydrophobic NAC region (residues 85-95) and the C terminus (residues 110-130), C-terminal 
residues 120-130 and residues 105-115, and the region around residue 120 and the N terminus 
around residue 20 (Bertoncini et al., 2005b; Bussell and Eliezer, 2001; Dedmon et al., 2005). 
   Upon incubation at 37 °C at a high concentration with agitation, recombinant αS assembles 
into fibrils that closely resemble those in the PD or DLB brain (Conway et al., 1998; Conway et 
al., 2000a).  Assembly of αS into αS fibrils (fαS) follows a nucleation-dependent process that 
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consists of a lag phase (nucleation) and a growth phase (elongation) (Wood et al., 1999).  The 
prevalence of fαS associated with LBD has led many researchers to hypothesize that they cause 
cell death (Duda et al., 2000; Spillantini et al., 1998).  However, recent evidence suggests that 
the earlier intermediates, αS oligomers may be more toxic components (Danzer et al., 2007; 
Karpinar et al., 2009; Outeiro et al., 2008; Wright et al., 2009). 
   αS, which is predominantly non-phosphorylated in vivo under normal conditions (Fujiwara et 
al., 2002), is extensively phosphorylated at Ser129 in α-synucleinopathic lesions (Fujiwara et al., 
2002; Nishie et al., 2004).  The specific phosphorylation of αS at Ser129 by casein kinase 2 
(Okochi et al., 2000; Pronin et al., 2000) resulted in accelerated oligomerization and formation of 
fαS (Fujiwara et al., 2002). 
   Mutations such as E46K, A30P and A53T have been reported to influence fαS formation in 
vitro (Conway et al., 1998; Conway et al., 2000b; Fredenburg et al., 2007; Giasson et al., 1999; 
Goldberg and Lansbury, 2000; Greenbaum et al., 2005; Narhi et al., 1999; Yonetani et al., 2009).  
The A53T mutation increased the propensity of fαS formation as well as the formation of 
protofibrils (Conway et al., 1998; Conway et al., 2000b; Giasson et al., 1999; Narhi et al., 1999).  
The A30P mutation promoted the formation of protofibrils but not that of fαS (Conway et al., 
2000b; Goldberg and Lansbury, 2000) and some of the protofibrils with a circular morphology 
formed pores by binding to the ER membrane (Volles and Lansbury, 2002).  The E46K 
mutation has also been reported to increase the propensity of fαS formation (Greenbaum et al., 
2005), and reduce the propensity of protofibrils by lower permeability of lipid vesicles 
(Fredenburg et al., 2007). 
   Here, we focused on the earliest stages of αS aggregation including monomer conformational 
dynamics and formation of low order oligomers of wild type (WT), E46K, A30P, A53T and 
A30P/A53T αS.  Our results showed that the E46K mutation produces αS peptides displaying 
accelerated statistical coil→α/β→β secondary structure transitions and an increased propensity to 
form relatively large oligomers, whereas the A30P mutation produces αS peptides displaying 
decelerated secondary structure transitions and a decreased propensity to form oligomers.  
These results that familial mutations have reverse effects on early stages of αS assembly may be 
useful for understanding the pathological mechanism of LBD. 
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Materials and methods 
 
Chemicals and reagents 
   Chemicals were obtained from Sigma-Aldrich Co. (St. Louis, MO) or Invitrogen (Carlsbad, 
CA) and were of the highest purity available.  Water was produced using a Milli-Q system 
(Millipore Corp., Bedford, MA). 
 
Peptides 
   The αS solutions were prepared as described previously (Ono and Yamada, 2006).  Briefly, 
wild-type αS (WT)(lot number 50306AS), E46K mutant αS (E46K) (lot number 90204ASK), 
A30P mutant αS (A30P) (lot number 10604ASP), A53T mutant αS (A53T) (lot number 
61803AST), and A30P/A53T mutant αS (A30P/A53T) (lot number 30104ASPT) (Fig. 1) were 
purchased from Recombinant Peptide Technologies (LLC, GA, USA) and were stored at –80°C.   
   αS peptides were dissolved at a nominal concentration of 70 μM in 20 mM Tris buffer, pH 
7.4.  After sonication for 1 min in a bath sonicator, the αS solution was centrifuged for 15 min 
at 16,000 × g.  We confirmed that pH of all samples were ≈ 7.6. 
 
Peptide aggregation 
   Each αS solution prepared above (0.6 ml aliquot) was placed in a 1 ml microcentrifuge tube.  
The tubes were incubated at 37°C for 0-7 days with agitation.  Note that for each sample at each 
time point analyzed, aliquots used for different experiments (see below) were taken from the 
same tube of αS, ensuring that valid correlations could be made for the data thus produced. 
 
Thioflavin S (ThS) binding 
   ThS solution contained 5 μM ThS (MP Biomedicals, LLC, Irvine, CA) and 50 mM of 
glycine-NaOH buffer, pH 8.5.  5-μL of each sample was added to 1 mL ThS solution, and then 
the mixtured was vortexed briefly (≈ 3 s).  Fluorescence was determined three times at intervals 
of 10 s using a Hitachi F-2500 fluorometer.  Excitation and emission wavelengths were 440 and 
521 nm, respectively.  Fluorescence was determined by averaging the three readings and 
subtracting the fluorescence of a ThS blank. 
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Circular dichroism spectroscopy (CD) 
   CD measurements were made by placing 200 μl of sample into a 1 mm path-length CD 
cuvette (World Precision Instruments, Sarasota, FL), and acquiring spectra in a J-805 
spectropolarimeter (JASCO, Tokyo, Japan).  The CD cuvettes were maintained on ice prior to 
introduction into the spectrometer.  Following temperature equilibration (≈20 min), spectra 
were recorded at 22°C in the range of ≈190–260 nm at 0.2 nm resolution with a scan rate of 100 
nm/min.  Ten scans were acquired and averaged for each sample.  Raw data were manipulated 
by smoothing and subtraction of buffer spectra according to the manufacturer’s instructions. The 
half-time (t1/2) for assembly-dependent conformational change was determined numerically from 
the formula ([ ]t  [ ]min ) / ([ ]max  [ ]min )  1 / 2 ; where molar ellipticity [θ] always is measured 
at 198 nm, [θ]t is molar ellipticity at time t, [θ]max is maximal ellipticity, and [θ]min is minimum 
ellipticity. 
 
Photo-induced cross-linking of unmodified proteins (PICUP) and sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
   Cross-linking of αS was photo-induced essentially as described (Bitan et al., 2001)(Ono et al., 
submitted).  Briefly, for αS, the general method was to mix 18 µl of peptide, at a nominal 
concentration of 70 µM, with 1 µl of 40 mM tris(2,2′-bipyridyl)dichlororuthenium(II) 
hexahydrate (Ru(bpy)) and 1 µl of 2 mM ammonium persulfate, both dissolved in 20 mM Tris 
buffer, pH 7.4.  Then the mixtures were irradiated for 1 s with visible light and the reaction was 
quenched with 1 µL of 1 M dithiothreitol (Invitrogen) in water.  The frequency distribution of 
monomers and oligomers was determined using SDS-PAGE and silver staining, as described 
(Bitan et al., 2001).  Briefly, 20 l of each cross-linked sample was electrophoresed on a 
10-20% gradient tricine gel and visualized by silver staining (SilverXpress, Invitrogen).  
Non-cross-linked samples were used as controls in each experiment.  Densitometry was then 
performed using a luminescent image analyzer (LAS 4000 mini, Fujifilm, Tokyo) and image 
analysis software (Multi gauge version 3.2, Fujifilm). 
 
Nucleation activity of cross-linked αS oligomers 
   αS peptides were dissolved in 20 mM Tris buffer, pH 7.4, to produce final concentrations of 
70 M. After sonication for 1 min using a bath sonicator, the peptide solutions were centrifuged 
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for 15 min at 16,000 × g.  fαS or cross-linked αS, of the E46K, A30P, A53T and A30P/A53T 
analogues, were also prepared at a concentration of 70 M in 20 mM Tris buffer, pH 7.4.  The 
sonicated fαS or cross-linked αS were added to the un-cross-linked peptides at a ratio of 10% 
(v/v). The mixtures were incubated at 37°C for 0–7 d without agitation. 
 
Electron microscopy (EM) 
   A 10 l aliquot of each sample was spotted onto a glow-discharged, carbon-coated Formvar 
grid (Okenshoji Co. Ltd, Tokyo, Japan) and incubated for 20 min.  The droplet was displaced 
with an equal volume of 2.5% (v/v) glutaraldehyde in water and incubated for an additional 5 
min.  Finally, the peptide was stained with 8 l of 1% (v/v) filtered (0.2 m) uranyl acetate in 
water (Wako Pure Chemical Industries Ltd, Osaka, Japan).  This solution was wicked off and 
then the grid was air-dried.  Samples were examined using a JEM-1210 transmission electron 
microscope.  The diameters of assemblies were measured using a 10 × magnifier eyepiece 
containing a graticule (Electron Microscopy Sciences).  
 
Atomic force microscopy (AFM) 
   Peptide solutions were characterized using a Nanoscope IIIa controller (Veeco Digital 
Instruments, Santa Barbara, CA) with a multimode scanning probe microscope equipped with a 
JV scanner.  All measurements were carried out in the tapping mode under ambient conditions 
using single-beam silicon cantilever probes.  A 10 μl aliquot of each sample was spotted onto 
freshly cleaved mica (Ted Pella, Inc., Redding, CA), incubated at room temperature for 5 min, 
rinsed with water, and then blown dry with air.  At least four regions of the mica surface were 
examined to confirm the homogeneity of the structures throughout the sample.  Mean particle 
heights were analyzed by averaging the measured values of eight individual cross-sectional line 






Assemblies of WT and mutant1 αS peptides 
   To determine the effects of E46K, A30P, A53T and A30P/A53T substitutions on αS 
assembly, we used a well characterized assay of fibril formation, thioflavin dye binding (LeVine, 
1993; LeVine, 1999; Naiki and Nakakuki, 1996).  We found that E46K, A53T and A30P/A53T 
αS peptides accelerated fαS formation compared with the WT αS peptide (Fig. 2).  On the other 
hand, A30P αS peptide decelerated fibril formation compared with WT αS peptide (Fig. 2).  To 
further determine the effects of E46K, A30P, A53T and A30P/A53T mutations on the details of 
fαS formation such as nucleation and elongation phases, we analyzed the lag time, growth rate 
and maximum intensity (Table 1).  Although the lag time meaning nucleation phase mainly was 
similar in WT and all mutant αS peptides, E46K, A53T and A30P/A53T αS peptides increased 
the growth rate meaning elongation phase compared with the WT αS peptide (Table 1).  On the 
other hand, the A30P peptide decreased the growth rate compared with the WT αS peptide 
(Table 1).  The overall activity of fαS formation was in the order of: E46K > A53T = 
A30P/A53T > WT > A30P.   
  We used EM to directly confirm the fαS formation of WT, E46K, A30P, A53T and 
A30P/A53T after incubation at 37 for 7 days.  WT and all mutant αS fibrils formed a 
uniformly long, non-branched filament structure and there were no clear differences 
morphologically (Fig. 3).  The diameters of WT (Fig. 3A), E46K (Fig. 3B), A30P (Fig. 3C), 
A53T (Fig. 3D) and A30P/A53T (Fig. 3E) fαS were 10.8 ± 0.4, 10.3 ± 0.5, 9.3 ± 0.4, 10.9 ± 0.4 
and 9.6 ± 0.9 (mean ± S.E., n =10) nm, respectively. 
 
Secondary structure dynamics of wild type and mutant αS peptides 
   To analyze the secondary structure dynamics of WT αS isoforms and mutants thereof, we 
monitored peptide folding and assembly systems by CD during 7 days of incubation at 37°C.  
All five peptides initially produced spectra consistent with primarily statistical coil (SC) 
secondary structure (Figs. 4A–E).  The major feature of these spectra was a large magnitude 
minimum centered at ≈198 nm.  To allow comparison of the kinetics among the five peptides, 
the half-time (t1/2) for the entire transition process was determined using [θ]198, which correlates 
with SC, as a metric (see Methods). 
  WT αS displayed substantial secondary structure changes during days 1–6 that were consistent 
                                                 
1 We refer to the E46K, A30P, A53T and A30P/A53T peptides as “mutants” only for ease in distinguishing them from 
WT αS. This designation does not refer directly to the corresponding DNA sequences. 
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with SC→/→ transitions associated with monomer→protofibril→fibril assembly (Fig. 4A).  
For WT αS, t1/2 was ≈ 1.5 d (Fig. 4F).  E46K αS displayed substantially accelerated kinetic, 
with t1/2 ≈ 0.6 d  (Figs. 4B and F).  Conformational change in E46K αS was complete by day 
2.  A30P αS displayed substantial secondary structure changes during days 1–6, with t1/2 ≈ 1.6 
d  (Figs. 4C and F).  The A53T and A30P/A53T αS peptides displayed slightly accelerated 
kinetics, with t1/2 ≈ 1.1 d (Figs. 4D, E and F).  Conformational changes in the A53T and 
A30P/A53T αS peptides were complete by day 5 and the spectra during days 1–5 were very 
similar.   The maximal value of d[θ]/dt of E46K αS was strikingly high, but similar for the 
other three mutant and WT αS peptides (Fig. 4F).   
 
αS oligomerization 
   To determine whether the E46K, A30P, A53T or A30P/A53T amino acid substitutions 
affected peptide oligomerization, we used PICUP, a photochemical cross-linking method that is 
rapid, efficient, requires no structural modification of peptides, and accurately reveals the 
oligomerization state of peptides (for a review, see Bitan and Teplow, 2004).  In the 
un-cross-linked controls, the WT αS peptide was comprised of primarily monomers (Fig. 5, lane 
1).  Similar patterns were observed for the homologous E46K, A30P, A53T or A30P/A53T αS 
peptides (Fig. 5, lanes 2-5).  When the oligomers were stabilized by cross-linking, WT αS was 
comprised of monomers to tetramers (Fig. 5, lane 6), whereas E46K αS was comprised of higher 
order species, including pentamers and hexamers (Fig. 5, lane 7).  The oligomers of A30P αS 
were comprised of monomers to trimers (Fig. 5, lane 8).  The oligomers of both A53T and 
A30P/A53T αS peptides showed a distribution similar to that of WT αS (Fig. 5, lanes 9 and 10).  
The oligomer/monomer ratios of WT, E46K, A30P, A53T and A30P/A53T αS peptides are 1.64 
± 0.12, 1.98 ± 0.07, 0.73 ± 0.02. 1.63 ± 0.12, and 1.68 ± 0.12, respectively (n=3, mean ± S.E.).  
We note that a new band appeared below the band corresponding to the monomer, which might 
be truncated αS by autocatalytic proteolysis. 
. 
 
αS assembly morphology 
   We examined the morphology of the oligomers formed immediately following peptide 
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dissolution by EM (Fig. 6; Table 2) and AFM (Fig. 7; Table 2).  Un-cross-linked αS of WT and 
all mutant αS peptides showed an irregular globular structure (Fig. 6).  The average diameter of 
the globular components was 2.17 ± 0.13 (mean ± S.E.) nm (Fig. 6A and Table 2).  Although 
un-cross-linked mutant αS peptides produced a similar globular structure, the average diameter 
of E46K (Fig. 6B), A30P (Fig. 6C), A53T (Fig. 6D) and A30P/A53T (Fig. 6E) un-cross-linked 
αS was 2.95 ± 0.34, 1.95 ± 0.30, 2.16 ± 0.19 and 2.16 ± 0.42 (mean ± S.E.) nm, respectively 
(Table 2).   
  The cross-linked oligomers of WT αS peptide were predominantly quasi-spherical or 
ellipsoidal globular with an average diameter of 10.85 ± 1.05 (mean ± S.E.) nm (Fig. 6F; Table 
2).  The cross-linked oligomers of A53T and A30P/A53T αS peptides had a similar morphology 
with a diameter of 10.79 ± 0.82 and 10.98 ± 0.97 nm, respectively (Fig. 6I and J; Table 2).  
Cross-linked oligomers of E46K αS had the largest globules with an average diameter of 14.97 ± 
1.81 nm (Fig. 6G; Table 2).  Relative to WT αS, E46K, A53T or A30P/A53T αS, cross-linked 
oligomers of A30P αS had smaller globules with an average diamter of 9.99 ± 0.58 nm (Fig. 6H; 
Table 2).   
   AFM studies showed similar results.  The average height of the globular components was 
0.50 ± 0.01 (mean ± S.E.) nm (Fig. 7A and Table 2).  Although un-cross-linked mutant αS 
peptides produced a similar globular structure, the average height of E46K (Fig. 7B), A30P (Fig. 
7C), A53T (Fig. 7D) and A30P/A53T (Fig. 7E) un-cross-linked αS was 0.65 ± 0.02, 0.36 ± 0.01, 
0.46 ± 0.01 and 0.44 ± 0.01 (mean ± S.E.) nm, respectively (Table 2).   
  The average height of cross-linked oligomers of WT αS peptide was 1.51 ± 0.12 (mean ± S.E.) 
nm (Fig. 7F; Table 2).  The cross-linked oligomers of A53T and A30P/A53T αS peptides had a 
similar morphology with a height of 1.46 ± 0.21 and 1.62 ± 0.15 nm, respectively (Fig. 7I and J; 
Table 2).  Cross-linked oligomers of E46K αS had the largest globules with an average height 
of 3.36 ± 0.44 nm (Fig. 7G; Table 2).  Relative to WT αS, E46K, A53T or A30P/A53T αS, 
cross-linked oligomers of A30P αS had smaller globules with an average height of 1.16 ± 0.17 
nm (Fig. 7H; Table 2).   
 
Nucleation of αS fibril assembly 
   αS assembly has characteristics of a nucleation-dependent polymerization process (Wood et 
al., 1999).  To study the abilities of fαS or oligomers of the WT and mutant αS peptides to 
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nucleate fibril formation, we monitored the time-dependence of ThS fluorescence in seeded fibril 
formation experiments (Fig. 8 and 9).  Thioflavin dye fluorescence does not measure fibril 
concentration per se (some fibrils do not possess the β-sheet structures to which Thioflavin dye 
binds) (Groenning, 2009), but the fluorescence intensity is correlated with fibril content (LeVine, 
1993; LeVine, 1999; Naiki and Nakakuki, 1996). 
 Un-seeded αS of WT displayed a quasi-sigmoidal process curve characterized by an ≈12 h lag 
time, an ≈108 h period of increasing ThS binding, and a binding plateau occurring after ≈120 h 
(Fig. 2)—results consistent with a nucleation-dependent polymerization process.  The unseeded 
reaction displayed no initial fluorescence increase (Fig. 2).  First, we examined nucleation 
activities of sonicated fαS.  Adding 10% (w/w) sonicated fαS of WT eliminated the lag period 
and produced a quasi-hyperbolic increase in fluorescence that reached maximal levels at ≈ 6 h 
(Fig. 8A).  Nucleation activity was displayed by other mutant fαS of E46K, A30P, A53T and 
A30P/A53T as well (Fig. 8A).  To compare these nucleation activities, each sonicated fαS was 
added to un-cross-linked WT αS (Fig. 8B).  Sonicated fαS of A53T and A30P/A53T displayed 
an almost identical time course in fluorescence that reached maximal levels at ≈ 4 h.  In the 
case of E46K, the initial rates of increase in ThS signal were ≈ 30 FU/h, and this rate was 
significantly (p < 0.001) greater than that produced by WT (≈ 17 FU/h), A53T (≈ 20 FU/h) or 
A30P/A53T fαS seeds (≈ 21 FU/h).  Maximal fluorescence was observed by ≈ 3 h using E46K 
fαS seeds.  On the other hand, in fαS of A30P, the initial rate of increase in ThS signal was ≈ 11 
FU/h, and this rate was significantly smaller than that of WT, E46K, A53T or A30P/A53T fαS 
seeds (p < 0.001).  Maximal fluorescence was observed by ≈ 72 h in the fαS seeds of A30P. 
 Next, we examined whether cross-linked αS oligomers displayed similar nucleation activity.  
Adding 10% (w/w) cross-linked αS oligomers of WT eliminated the lag period and produced a 
quasi-hyperbolic increase in fluorescence that reached maximal levels at ≈72 h (Fig. 9A).  
Stable WT αS oligomers thus functioned as fibril nuclei.  Nucleation activity was displayed by 
other mutant αS peptides, E46K, A30P, A53T and A30P/A53T oligomers as well (Fig. 9A).  To 
compare these nucleation activities, each cross-linked oligomer of αS was added to 
un-cross-linked WT αS (Fig. 9B). Similarly to cross-linked αS oligomers of WT, cross-linked αS 
oligomers of A53T and A30P/A53T displayed an almost identical time course in fluorescence 
that reached maximal levels at ≈72 h.  In the case of E46K, the initial rates of increase in ThS 
signal were ≈12 FU/h, and this rate was significantly (p < 0.001) greater than that produced by 
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WT, A53T or A30P/A53T αS seeds (≈3.5 FU/h).  Maximal fluorescence was observed by ≈48 
h using E46K αS seeds, compared to ≈72 h using WT, A53T or A30P/A53T αS seeds.  On the 
other hand, in A30P αS, the initial rate of increase in ThS signal was ≈0.6 FU/h, and this rate was 
significantly smaller than that produced by WT, E46K, A53T or A30P/A53T αS seeds (p < 
0.001).  Maximal fluorescence was observed by ≈120 h using A30P αS seeds.   
 
Secondary structures of wild type and mutant αS assemblies 
αS has been shown to exist predominately as a statistical coil if prepared under conditions 
designed to prevent its folding and self-assembly (Li et al., 2002).  However, as shown above, 
peptide folding and assembly is a dynamic process involving an overall SC→α-helix→β-sheet 
transition.  To determine the conformational states of the stable oligomers formed by the five 
peptides, CD was performed following cross-linking.  Un-cross-linked αS of WT displayed 
spectra consistent with the SC state (Supplementary Fig. 1A).  The major features of these 
spectra were a substantial minimum centered at ≈198 nm and an inflection point at ≈225 nm.  In 
contrast, the major spectral feature displayed by the cross-linked oligomers of WT αS peptide 
was a population comprising mixture of α-helix and β-sheet conformers (Supplementary Fig. 1A).  
The spectra of un-cross-linked and cross-linked αS peptides of E46K (Supplementary Fig. 1B), 
A30P (Supplementary Fig. 1C), A53T (Supplementary Fig. 1D) and A30P/A53T 




  The etiology of LBD is complex, but the aggregation of αS has been suggested to be a seminal 
pathogenetic agent (Brown, 2010; Ono et al., 2008; Uversky, 2007).  Three missense mutations 
in the αS gene have been identified in familial cases of early onset PD or LBD: the A53T 
mutation in a large Italian-American family with PD, known as the Contursi kindred 
(Polymeropoulos et al., 1997); the A30P mutation in a German family with PD (Kruger et al., 
1998); and the E46K mutation in a Spanish family with LBD characterized by autosomal 
dominant parkinsonism, dementia, and visual hallucinations of variable severity (Zarranz et al., 
2004).  These findings suggest that a single mutation in the human αS gene is sufficient to 
result in the LBD phenotype (Uversky, 2007).  By studying these mutations we may find out 
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some clues of the biophysical basis for disease causation.  We found, relative to peptides 
containing the WT αS N terminal sequence, that E46K mutations facilitated fαS formation as 
well as secondary transition, oligomerization, and produced larger oligomeric assemblies, 
whereas A30P mutations decreased them.  Stable oligomers of E46K αS were more potent 
nucleators of higher-order assembly than were WT oligomers, whereas those of A30P αS were 
weaker nucleators of higher-order assembly. 
  First, we examined how E46K, A30P, A53T or A30P/A53T influenced fαS formation using 
ThS binding and EM assays in vitro.  We found that E46K, A53T and A30P/A53T αS 
accelerated the formation of fαS, especially the elongation process compared with WT, whereas 
A30P αS decelerated the formation of fαS, especially the elongation process.  The overall 
activity of fαS formation was in the order of: E46K > A53T = A30P/A53T > WT > A30P.  All 
mutations have been reported to influence the propensity of fαS formation, but the results are not 
necessarily consistent.  Narhi et al. (Narhi et al., 1999) reported accelerated fαS formation for 
all A30P, A53T and A30P/A53T mutants; A30P αS formed fαS slightly faster than WT αS, and 
both A53T and A30P/A53T αS formed much faster.  Conway et al. (Conway et al., 1998; 
Conway et al., 2000b) reported that the A53T mutation increased the propensity of fαS formation, 
but the A30P mutation did not.  There are a few reports that the A30P mutation decreased fαS 
formation, especially the nucleation phase (Conway et al., 2000b; Yonetani et al., 2009).  The 
E46K mutation has been reported to increase the propensity of fαS formation, but this effect was 
less pronounced than that of the A53T mutation (Greenbaum et al., 2005).  This discrepancy 
may be due to the difference of sample preparation such as buffer, pH and αS concentration. 
  Second, we studied the conformational dynamics of the αS systems.  Examination of 
temporal changes in secondary structure revealed that E46K, A53T and A30P/A53T mutations 
accelerated the rate of the SC→α-helix→β-sheet transition; the change of E46K αS was much 
faster than that of WT αS, and those of both A53T and A30P/A53T αS were slightly faster.  
Especially, the acceleration of E46K αS was ~2.5-fold as determined by the t1/2 for the transition, 
and the maximal observed transition rate from SC to ordered secondary structures of E46K αS 
was biggest among the five different αS peptides.  The change of A30P αS was slightly slower 
than that of WT αS.  These results were compatible with the results of fαS formation, and 
suggest that the αS mutations cause substantial changes in peptide structural order that influence 
monomer folding and are necessary for higher-order assembly, including oligomerization and 
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fibril nucleation and elongation.    
  Third, we focused primarily on the oligomerization process, which is hypothesized to be the 
most important process in LBD pathobiology (Danzer et al., 2007; Karpinar et al., 2009; Outeiro 
et al., 2008; Wright et al., 2009).  The E46K αS produced an oligomer distribution in which the 
highest observed oligomer order exceeded that of the WT αS.  By contrast, the A30P αS 
produced an oligomer distribution with a lower oligomer order than the WT αS.  The oligomer 
size frequency distribution is controlled by the proximity, chemical reactivity, and chemical 
accessibility of amino acid side-chains, predominantly the phenol group of Tyr (Bitan and 
Teplow, 2004; Fancy et al., 2000; Fancy and Kodadek, 1999).  The change in order was 
accompanied by a change in size, as determined by AFM (z-axis value) analyses.  Cross-linked 
oligomers of WT and mutant αS were smaller than those reported by other groups (Giehm et al., 
2011; Kim et al., 2009).  In our study, E46K αS produced an assembly with larger oligomers 
than WT αS, whereas A30P αS produced an assembly with smaller oligomers.  These data were 
consistent with our determination of oligomer size frequency distribution, which showed 
skewing toward higher or lower order with the mutant peptides.  We recently reported that a 
direct correlation between oligomer order and size, that is, that higher-n order oligomers have 
larger particles in the Aβ system (Ono et al., 2009; Ono et al., 2010).  The stabilized oligomers 
in each system showed a consistent rank order of size, E46K > A53T = A30P/A53T = WT > 
A30P.  Although dynamic light scattering studies showed faster oligomerization in A30P and 
A53T αS than in WT αS (Karpinar et al., 2009), a detailed biochemical analysis has not been 
reported.   
  Since the effect of the mutation on the αS assembly process should help to understand the 
disease mechanism(s) of LBD, we examined the relative ability of fαS as well as stabilized 
oligomers to nucleate the assembly of ThS-positive structures.  We found that αS exhibited a 
substantial lag period (≈0.5 d) that was eliminated by addition of WT and mutant oligomers 
although this nucleation activity of each αS oligomer was smaller than that of each fαS.  The 
rank order of the rates of propagation of ThS-positive structure (dFU/dt) was E46K > A53T = 
A30P/A53T = WT > A30P.  These mutations facilitate the structural organization of αS, and 
the structure(s) thus formed are potent nucleators of the assembly of the ThS-positive αS 
structure. 
  What type of structural effects might be caused by these αS mutations?  Two classes of 
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effects exist, local and global.  By definition, the local effects include alteration in peptide chain 
structure at or immediately adjacent to the sites of the amino acid substitutions. It is not clear 
whether local folding motifs may be affected.  What is clear is that the oligomerization process 
is affected.  Again, by definition, this means that intermolecular interactions must be altered. 
We can speculate three mechanisms of the alteration: (1) the same monomer folding necessary 
for oligomerization as that of WT αS peptide influences occurrence frequency of other mutated 
αS oligomerization and the same residues mediating the intermolecular interactions with the WT 
αS peptide are involved in other mutated αS (but do not include Pro30, Lys46, or Thr53); (2) 
intermolecular interactions involving Lys46 or Thr53 are more stable than those involving Glu46 or 
Ala53, whereas the interactions involving Pro30 are less stable than those involving Ala30; and (3) 
a different monomer folding that influences a propensity for self-association but which may or 
may not require direct intermolecular interactions involving Pro30, Lys46, or Thr53 occurs.   
  Structurally, αS in its free state shows a weak propensity for a helical structure throughout the 
N-terminal lipid-binding domain and a preference for more extended conformations in the acidic 
C-terminal region (Eliezer et al., 2001).  Intramolecular contacts between the acidic C-terminal 
tail of αS and its N-terminal region have been proposed to regulate αS assembly, A30P and 
A53T mutations have been reported to lead to a local decrease in the helical propensity of the 
protein – an effect that has been proposed to facilitate the assembly of these two mutants into the 
β-sheet-rich conformers (Bussell and Eliezer, 2001).  The presence of an amphipathic helical 
structure, combined with the known role of the hydrophic NAC region of αS in mediating 
intermolecular interactions, also led to the hypothesis that transient long-range intramolecular 
contacts could protect αS from self-assembly (Bussell and Eliezer, 2001).  NMR studies 
confirmed the presence of long-range contacts in αS, but they were observed predominantly 
between the acidic C-terminal tail and both the NAC region and a region near the N-terminus of 
the protein (Bertoncini et al., 2005b; Dedmon et al., 2005).  Although a subsequent report 
indicated that the A30P and A53T mutations disrupt these long-range interactions, and this effect 
was also proposed to underlie the ability of these mutations to facilitate αS assembly in vitro 
(Bertoncini et al., 2005a), different effects on intramolecular interactions have not been reported.  
Surprisingly, Rospigliosi et al. (Rospigliosi et al., 2009) reported that the E46K mutation did not 
interfere with C-terminal-to-N-terminal contacts but rather enhanced such contacts, and that 
A30P and A53T mutations reduced such contacts.  They suggested that 
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C-terminal-to-N-terminal contacts in αS did not strongly influence self-assembly, and that the 
dominant mechanism by which these PD-linked mutations facilitate αS assembly may be altering 
the physicochemical properties of the protein such as net charge (E46K) and secondary structure 
propensity (A30P and A53T) (Rospigliosi et al., 2009).  Further mechanistic studies focused on 
αS N terminal structural dynamics are needed.  
  A clear difference in onset age or clinical course between mutations has not been reported.  
Dementia was common in families with both A53T and E46K mutations (Kruger et al., 1998; 
Polymeropoulos et al., 1997; Zarranz et al., 2004), but uncommon in a family with the A30P 
mutation (Kruger et al., 1998; Polymeropoulos et al., 1997; Zarranz et al., 2004).  The 
levodopa-response was good in a family with A30P or A53T mutation, but was limited in the 
early stage of the disease in a family with LBD with E46K mutation (Zarranz et al., 2004).  The 
patients in a family with E46K mutation had a cognitive deficit in the early stage of disease and 
DLB pathology; a high density of LBs was present not only in the subcortical nuclei but also in 
the parahippocampus, amygdala and cortex (Zarranz et al., 2004).  The patients in families with 
the A30P or A53T mutation also exhibited diffuse LBs pathology (Markopoulou et al., 2008; 
Seidel et al., 2010).  Although the widespread distribution of LBs formation in LBD with the 
E46K mutation (Zarranz et al., 2004) may be related to accelerated assembly of E46K αS 
observed in our study, it is difficult to correlate our in vitro results to clinicopathological findings 
reported in patients with these mutations.  Other proteins such as transcriptional cofactor high 
mobility group protein 1, brain-specific protein p25 α tublin, and aglin have been identified as 
components of LBs (Alim et al., 2002; Lindersson et al., 2005; Lindersson et al., 2004; Liu et al., 
2005).  A difference in the interaction of αS with these proteins may be responsible for the 
difference in αS aggregation and LBs formation among WT and mutant αS peptides. 
  In conclusion, E46K αS accelerated the kinetics of the secondary structure change and 
oligomerization, whereas A30P αS decelerated them.  These effects were reflected in changes 
in average oligomer size and activities as nucleators of the self-assembly process.  The mutant 
oligomers of E46K αS functioned as fibril seeds significantly more efficiently than those of WT 
αS, while the mutant oligomers of A30P αS were less efficient.  Our results that familial 
mutations had opposite effects at early stages of αS assembly may provide new insight into the 
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Fig. 1. Amino acid sequences of αS. 
 
Fig. 2. ThSbinding. 70 M αS of WT (○), E46K (△), A30P ( ), A53T (◇) or A30P/A53T 
(▼) was incubated at 37 °C for 7 days in 20 mM Tris buffer, pH 7.4. Periodically, aliquots were 
removed and ThS binding levels were determined. Binding is expressed as mean fluorescence (in 
arbitrary fluorescence units (FU)) ± S.E. Each figure comprises data obtained with 3 independent 
experiments. 
 
Fig. 3. αS assembly morphology. EM was used to determine the morphologies of assemblies of 
αS. 70 M αS of WT (A), E46K (B), A30P (C), A53T (D) or A30P/A53T (E) was incubated at 
37 °C for 7 days in 20 mM Tris buffer, pH 7.4. Scale bars indicate 100 nm.  
 
Fig. 4. αS secondary structure dynamics. 70 M αS of WT (A), E46K (B), A30P (C), A53T 
(D) or A30P/A53T (E) was incubated at 37 °C for 7 days in 20 mM Tris buffer, pH 7.4. Spectra 
were acquired immediately at the start of the incubation period, d 0 (○), and after days 1 (▼), 2 
(□), 3 ( ), 4 (◇), 5 (▲), 6 (▽) and 7 (◆). The spectra presented at each time are representative 
of those obtained during each of 3 independent experiments. (F) Molar ellipticity []198 versus 
time for αS.  
 
Fig. 5. αS oligomerization. PICUP, followed by SDS-PAGE and silver staining, was used to 
study oligomerization of 70 M αS of WT, E46K, A30P, A53T or A30P/A53T. Lane 1, 
un-cross-linked αS of WT; Lane 2, un-cross-linked αS of E46K; Lane 3, un-cross-linked αS of 
A30P; Lane 4, un-cross-linked αS of A53T; Lane 5, un-cross-linked αS of A30P/A53T; Lane 6, 
cross-linked αS of WT; Lane 7, cross-linked αS of E46K; Lane 8, cross-linked αS of A30P; Lane 
9, cross-linked αS of A53T; Lane 10, cross-linked αS of A30P/A53T. The gel is representative of 
three independent experiments. 
 
Fig. 6. EM analysis of αS oligomers. EM was performed on 70 M un-cross-linked (A-E) and 
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cross-linked (F-J) αS of WT (A, F), E46K (B, G), A30P (C, H), A53T (D, I) or A30P/A53T (E, 
J) peptide. Scale bars are 100 nm. 
 
Fig. 7. AFM analysis of αS oligomers. AFM was performed on 70 M un-cross-linked (A-E) 
and cross-linked (F-J) αS of WT (A, F), E46K (B, G), A30P (C, H), A53T (D, I) or A30P/A53T 
(E, J) peptide. Scale bars are 100 nm. 
 
Fig. 8. Nucleation activities of sonicated αS fibrils. (A) 10% (v/v) sonicated αS fibrils (Fib) of 
WT (○), E46K (△), A30P (  ), A53T (◇) or A30P/A53T (▼) was added to each 
un-cross-linked (UnXL) αS, which then was incubated for 7 days at 37 C in 20 mM Tris buffer, 
pH 7.4. (B) 10% (v/v) sonicated αS fibrils (Fib) of WT (○), E46K (△), A30P ( ), A53T (◇) or 
A30P/A53T (▼) was added to un-cross-linked (UnXL) WT αS, which then was incubated for 4 
days at 37 C in 20 mM Tris buffer, pH 7.4. Aliquots were assayed periodically using ThS. 
Binding is expressed as mean fluorescence (in arbitrary fluorescence units (FU))  S.E. Each 
figure comprises data obtained with 3 independent experiments. 
 
Fig. 9. Nucleation activities of αS oligomers. (A) 10% (v/v) cross-linked (XL) WT (○), E46K 
(△), A30P (  ), A53T (◇) or A30P/A53T (▼) oligomers of αS was added to each 
un-cross-linked (UnXL) αS, which then was incubated for 7 days at 37 C in 20 mM Tris buffer, 
pH 7.4. (B) Zero % (v/v) (●) or 10% (v/v) cross-linked (XL) WT (○), E46K (△), A30P ( ), 
A53T (◇) or A30P/A53T (▼) oligomers of αS was added to un-cross-linked (UnXL) WT αS, 
which then was incubated for 7 days at 37 C in 20 mM Tris buffer, pH 7.4. Aliquots were 
assayed periodically using ThS. Binding is expressed as mean fluorescence (in arbitrary 




Supplementary Fig. 1. Secondary structures of αS oligomers. The spectra of un-cross-linked 
(○) or cross-linked (●) αS of WT (A), E46K (B), A30P (C), A53T (D), or A30P/A53T (E) were 





Table 1. Kinetics of αS assembly 
 
Sample Lag time (d)a Growth Rate (FU/d)b 
Maximum Intensity 
(FU)c 
WT αS 0.5 10.4 40.4 
E46K αS 0.3 25.4 44.9 
A30P αS 0.5 8.2 39.6 
A53T αS 0.3 13.1 39.5 
A30P/A53T αS 0.3 12.5 39.4 
 
a-Lag time was defined as the point of intersection with the abscissa of the line determined by the 
pseudo-linear portion of the fluorescence progress curve, according to Evans et al. (Evans et al., 
1995). 
b-Growth rate was determined by line fitting to the pseudo-linear segment of the ascending 
portion of the fluorescence progress curve. 
c-Determined by visual inspection. 
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Table 2. Morphological Analysis of S Assemblies a 
 
Assembly Diameter a Height b 
Un-cross-linked WT 2.17 + 0.13 (19)  0.50 + 0.01 (113) 
Un-cross-linked E46K 2.95 + 0.34 (23) 0.65 + 0.02 (95) 
Un-cross-linked A30P 1.95 + 0.30 (19)  0.36 + 0.01 (138) 
Un-cross-linked A53T 2.16 + 0.19 (25)  0.46 + 0.01 (89)  
Un-cross-linked A30P/A53T 2.16 + 0.42 (26)  0.44 + 0.01 (88)  
Cross-linked WT 10.85 + 1.05 (16)  1.51 + 0.12 (40)  
Cross-linked E46K 14.97 + 1.81 (19)  3.36 + 0.44 (23)  
Cross-linked A30P  9.99 + 0.58 (19)  1.16 + 0.17 (20)  
Cross-linked A53T 10.79 + 0.82 (23)  1.46 + 0.21 (27)  
Cross-linked A30P/A53T 10.98 + 0.97 (14)  1.62 + 0.15 (37)  
a-Mean diameter + S.E., in nm, is listed for (n) S assemblies visualized by EM. 
b- Mean height + S.E., in nm, is listed for (n) S assemblies visualized by AFM. 
 
